SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical : Pharmacyclics (PCYC)
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  
To: Miljenko Zuanic who wrote (655)12/13/2001 9:56:38 PM
From: scaram(o)uche  Read Replies (1) of 717
 
As Rick said in '97 (and I was very concern from day one about high doses and BBB):

RE:CEO
"Vuk dlaku mijenja, ali cud ne!"

I don't want to know.

:-)

When he was Idec, I was very clearly and loudly saying that Specifid didn't have a frigging chance of reaching "product status".

When he was at CellPro, I was very clearly and loudly saying that the BD/JHU patent was sound and that the company was toast.

While he's been at PCYC, Bernhard and colleagues [thank you, Dr. Martin Brown!!.... I was seduced, again, post-Gadolite, and your work saved my butt] were very clearly and loudly saying that Gd-tex didn't have a chance.

Isn't it "three strikes and you're out"?

Very bad for biotech. Fortunately, there aren't too many of these management teams left.
Report TOU ViolationShare This Post
 Public ReplyPrvt ReplyMark as Last ReadFilePrevious 10Next 10PreviousNext  

HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News